TIF
Issue 62 – March 2013
Latest News:
- FDA Approves Oxbryta™ (Voxelotor), the First Medicine Specifically Targeting the Root Cause of Sickle Cell Disease
- TIF will coordinate efforts for patients’ information on Reblozyl in 62 countries
- New and Updated Data on Key Thalassaemia & SCD Pipeline Therapies at the American Society of Hematology (ASH) 2019 Annual Meeting – 7-10 December 2019
- Deferasirox Mylan: A new generic drug for the treatment of iron overload in β-thalassaemia major obtained approval by the EMA
- US government & Gates Foundation pledge $200 million to bring gene therapies to patients with Sickle Cell Disease & HIV
